|
Peter Rost, M.D. is a former drug marketing executive and is most well known for taking public stances critical of the pharmaceutical industry as an "insider" and whistleblower. He sued his last two pharmaceutical employers, Wyeth and Pfizer, the latter of which fired him in 2005. At Wyeth, he uncovered tax evasion practices, and after informing senior company executives, was transferred from Sweden to a post in New Jersey. Rost sued the company, saying that the transfer was a retaliatory demotion, though the company said it was a promotion. Rost settled with Wyeth for an undisclosed amount in 2003. At Pfizer, Rost filed a qui tam suit disclosing off-label marketing of Genotropin at Pharmacia prior to its purchase by Pfizer. The U.S. Department of Justice declined to join in Rost's suit as the marketing violations had already been disclosed to the Department by Pfizer.〔 Rost was eventually fired by Pfizer, and sued for wrongful dismissal, but this lawsuit was summarily dismissed by the the court based on evidence that Pfizer had decided to fire Rost prior to discovery of his whistleblowing activities. Since then, Rost has worked outside the pharmaceutical industry, as a public speaker, blogger, writer, and litigation consultant. ==Biography== Rost worked at medical advertising agencies prior to starting to work for pharmaceutical companies.〔Jim Edwards for BrandWeek. March 20, 2006. ''(Bad Medicine. )'' BrandWeek. (Original link broken ), Created link from internet archive on August 9, 2014. Archive date March 28, 2006.〕 Rost started working at Wyeth in approximately 1992; seven years after joining Wyeth, he was promoted to head Wyeth-Lederle Nordiska, Wyeth's Scandinavian subsidiary, and Rost has said that he doubled sales during his tenure. He became concerned about Wyeth's accounting practices and informed upper management of his concerns. Shortly thereafter, he was transferred from Sweden to New Jersey, a move he characterized as a retaliatory demotion. He filed a lawsuit against Wyeth, that was settled out of court for undisclosed terms.〔David Cay Johnson and Melody Petersen for the New York Times. January 17, 2003 (Whistle-Blower Accuses Wyeth Of Tax Dodges )〕 Rost left Wyeth for Pharmacia in June 2001 and took a role leading its endocrinology division, and said that he soon began to be concerned from a business perspective about sales of Genotropin, Pfizer's human growth hormone drug, which had plateaued; Pharmacia's decision to pour money into off-label marketing to adults was not paying off, due to the low doses that adults took. In the next year, Rost became aware that the strategy was not only unwise, but was probably illegal, and began raising objections internally to try to get the company to change course.〔 In July 2002 merger discussions with Pfizer were announced, and Rost and other executives briefed the Pfizer acquisition team on the issues with Genotropin as the merger talks progressed.〔 However, when news broke in January 2013 of Rost's lawsuits against Wyeth (see below), things turned sour; Rost reported getting an email from his future Pfizer boss saying "There will not be a fit with the marketing organization" for him.〔 The merger with Pfizer was completed in April 2003.〔 Rost was offered a severance package, as other Pharmacia executives were, but Pfizer and Rost failed to come to agreement, and Pfizer did not fire him, as they were aware of the suit he filed against them related to Genotropin marketing (see below).〔 His staff of 60 was slowly reassigned and by the end of summer 2003, he was left with his administrative assistant, who was re-assigned in the summer of 2004, and his office was moved to an out of the way location.〔 In August 2004, Rost posted a glowing review of Marcia Angell's book, ''The Truth About the Drug Companies: How They Deceive Us and What to Do About It'' on amazon.com.〔Peter Rost, customer review at Amazon.com. August 25, 2004 (Fantastic Reading )〕 The review was noticed by a reporter at USA Today, which interviewed him for an article on the drug industry.〔By Rita Rubin for USA Today. September 13, 2004 (Prescription for reform? )〕 The public spotlight from the USA Today article "changed Rost’s life" and launched Rost's new career as an insider critical of the drug industry.〔〔Jake Whitney for Guernica Magazine. June 11, 2008 (Healthscare: Jake Whitney interviews Peter Rost )〕 In September 2004 Rost testified at a Congressional hearing over the reimportation of drugs, in which he stated that "Holding up a vote on importation, stopping good importation bills has a high, high cost not just in money, but in American lives. Every day we delay, Americans die because they cannot afford life-saving drugs." Pfizer responded by sending a letter to Congress that said, "Dr. Rost has no qualifications to speak on importation, no responsibilities in this area at Pfizer, no knowledge of the information and analysis Pfizer has provided to the government on this issue, and no substantive grasp of how importation may impact the safety of this nation's drug supply."〔Robert Pear for the New York Times. September 24, 2004 ( Insider Challenges Drug Industry on Imports )〕 Rost followed up that testimony with an opinion piece published by the New York Times.〔Peter Rost. Opinion piece in the New York Times. October 30, 2004 (Medicines Without Borders )〕 In mid 2005 Rost appeared on a 60 Minutes segment about drug pricing.〔Alex Berenson for the New York Times. June 8, 2005 (At Pfizer, the Isolation Increases for a Whistle-Blower )〕 In late 2005 Rost's lawsuit against Pfizer under the False Claims Act was unsealed (see below) and in December 2005, Pfizer fired him.〔Alex Berensen for the New York Times. December 2, 2005 (Pfizer Fires a Vice President Who Criticized the Company's Sales Practices )〕 At Pfizer, Rost had made $600,000 per year for "by his own account, doing essentially no work".〔 Rost filed an unlawful termination suit against Pfizer that was summarily dismissed. The court ruled that the evidence showed Pfizer had decided to fire Rost prior to learning of his whistleblowing activities. According to Pfizer, Rost's public criticism came only after he asked for and was denied a $10M severance package.〔 Rost started blogging at The Huffington Post, but was banned in June 2006, after he got into a tiff with a heckler on his blog, who turned out to be on the Post's technical staff. Arianna Huffington said, "It seemed like his blog was becoming about personal grudges. That would have been no problem if the posts were interesting."〔Maria Aspan for the New York Times. June 26, 2006 (A Blogger Is Bounced From the Huffington Post )〕 In September 2006, Rost's book, ''The Whistleblower, Confessions of a Healthcare Hitman'' was published, which described Rost’s tenure at Pharmacia and Pfizer and his efforts to deal with the marketing of Genotropin.〔 In 2007, he published ''Killer Drug'', a novel about a fictional drug company that develops a biological weapon for the military.〔 In August 2007 Rost started to write a daily blog for BrandweekNRX〔(BrandweekNRX August 2007 )〕 and a column for Realtid,〔(Realtid.se )〕 a Swedish online business newspaper. Later in 2007 Rost announced his new business venture, as a Pharmaceutical Marketing Expert Witness.〔(Rost's Litigation Consultant website )〕〔(Peter Rost's personal blog )〕 Rost was featured in the award-winning documentary film Fire in the Blood (2013 film).〔David Rooney for Hollywood Reporter. January 18, 2013 ( Fire in the Blood: Sundance Review )〕 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「Peter Rost (doctor)」の詳細全文を読む スポンサード リンク
|